Swedish parents most pressured in the Nordics – everyday life takes its toll on the family - Metro Mode

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

IntroductionHow does the gut microbiome change as we age? The link between gut microbiome changes and inflammationGut microbiome and age-related health conditionsCan the gut microbiome be targeted to promote longevity? From microbial shifts in later life to the distinctive gut communities of centenarians, researchers are investigating what the intestinal microbes reveal about how people age.

IntroductionClinical trial evidenceFDA approval and regulatory developmentsCardiometabolic and secondary benefitsFuture directionsReferences What can treatments targeting weight and metabolism offer people with obstructive sleep apnea, and which questions must clinical trials still answer?

A common liver disease affecting nearly 30% of adults worldwide is far more complex than previously understood. Researchers at Mayo Clinic have identified five biologically distinct forms of the condition, each associated with different risks of serious health complications, including heart disease, liver failure, cancer, and the need for a liver transplant. The findings, published in Nature Communications, come from a collaboration between Mayo Clinic and Virginia Tech. Scientists discovered that metabolic dysfunction-associated steatotic liver disease, or MASLD, can develop through several different biological pathways. Some are closely connected to obesity and diabetes, while others appear to be driven by inherited genetic differences.